Identification of a novel population of Langerin+ dendritic cells

Journal of Experimental Medicine - Tập 204 Số 13 - Trang 3147-3156 - 2007
Laura S. Bursch1,2, Liang‐Chun Wang1,2, Botond Z. Igyártó3,2, Adrien Kissenpfennig4, Bernard Malissen4, Daniel H. Kaplan3,2, Kristin A. Hogquist1,2
11Department of Laboratory Medicine and Pathology
23Center for Immunology, University of Minnesota, Minneapolis, MN 55455
32Department of Dermatology
44Centre d'Immunologie de Marseille-Luminy, Institut National de la Santé et de la Recherche Médicale-Centre National de la Recherche Scientifique, Université de la Méditerranée Parc Scientifique et Technologique de Luminy, Case 906, 13288 Marseille, Cedex 09, France

Tóm tắt

Langerhans cells (LCs) are antigen-presenting cells that reside in the epidermis of the skin and traffic to lymph nodes (LNs). The general role of these cells in skin immune responses is not clear because distinct models of LC depletion resulted in opposite conclusions about their role in contact hypersensitivity (CHS) responses. While comparing these models, we discovered a novel population of LCs that resides in the dermis and does not represent migrating epidermal LCs, as previously thought. Unlike epidermal LCs, dermal Langerin+ dendritic cells (DCs) were radiosensitive and displayed a distinct cell surface phenotype. Dermal Langerin+ DCs migrate from the skin to the LNs after inflammation and in the steady state, and represent the majority of Langerin+ DCs in skin draining LNs. Both epidermal and dermal Langerin+ DCs were depleted by treatment with diphtheria toxin in Lang-DTREGFP knock-in mice. In contrast, transgenic hLang-DTA mice lack epidermal LCs, but have normal numbers of dermal Langerin+ DCs. CHS responses were abrogated upon depletion of both epidermal and dermal LCs, but were unaffected in the absence of only epidermal LCs. This suggests that dermal LCs can mediate CHS and provides an explanation for previous differences observed in the two-model systems.

Từ khóa


Tài liệu tham khảo

2002, J. Invest. Dermatol., 118, 117, 10.1046/j.0022-202x.2001.01631.x

2003, J. Invest. Dermatol., 120, 266, 10.1046/j.1523-1747.2003.12042.x

2004, Immunity., 21, 391, 10.1016/j.immuni.2004.07.019

1967, J. Cell Biol., 35, 468, 10.1083/jcb.35.2.468

2000, Immunity., 12, 71, 10.1016/S1074-7613(00)80160-0

2005, Mol. Cell. Biol., 25, 88, 10.1128/MCB.25.1.88-99.2005

2002, Nat. Immunol., 3, 1135, 10.1038/ni852

2003, Science., 301, 1925, 10.1126/science.1087576

2006, J. Immunol., 177, 1250, 10.4049/jimmunol.177.2.1250

2004, J. Exp. Med., 199, 725, 10.1084/jem.20030795

2004, Eur. J. Immunol., 34, 715, 10.1002/eji.200324391

2004, Eur. J. Immunol., 34, 1542, 10.1002/eji.200324586

2005, Immunity., 22, 643, 10.1016/j.immuni.2005.04.004

2005, J. Cell Biol., 169, 569, 10.1083/jcb.200501071

2005, Immunity., 23, 611, 10.1016/j.immuni.2005.10.008

2004, J. Invest. Dermatol., 123, 876, 10.1111/j.0022-202X.2004.23427.x

1998, J. Invest. Dermatol., 111, 7, 10.1046/j.1523-1747.1998.00243.x

1996, Eur. J. Immunol., 26, 110, 10.1002/eji.1830260117

2005, J. Invest. Dermatol., 125, 983, 10.1111/j.0022-202X.2005.23951.x

2006, J. Immunol., 176, 2161, 10.4049/jimmunol.176.4.2161

2006, Nat. Immunol., 7, 265

1999, J. Exp. Med., 190, 1755, 10.1084/jem.190.12.1755

2004, Immunity., 21, 279, 10.1016/j.immuni.2004.06.014

2007, J. Immunol., 179, 886, 10.4049/jimmunol.179.2.886

2007, Nat. Med., 13, 367, 10.1038/nm1541

2003, Immunol. Res., 28, 93, 10.1385/IR:28:2:93

2004, Proc. Natl. Acad. Sci. USA., 101, 8670, 10.1073/pnas.0402644101

1988, Proc. Natl. Acad. Sci. USA., 85, 8633, 10.1073/pnas.85.22.8633

1992, J. Exp. Med., 176, 47, 10.1084/jem.176.1.47

1997, J. Clin. Invest., 100, 575, 10.1172/JCI119567

2007, J. Immunol. Methods., 324, 48, 10.1016/j.jim.2007.05.001